8-KThe WireRoutine
Shareholder Vote
Filed Apr 20, 2026 · 2mo ago · Accession 0000049071-26-000015
Plain English
Material event — a significant development the company must disclose promptly.
Read the source below for the full document.
Filing text
View original ↗UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 20, 2026 ( April 16, 2026 )
Humana Inc.
(Exact name of registrant as specified in its charter)
Delaware 001-5975 61-0647538
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
101 East Main Street , Louisville , Kentucky 40202
(Address of principal executive offices, including zip code)
( 502 ) 580-1000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Common Stock HUM New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
The regular annual meeting of the stockholders of Humana Inc. (the “Company”) was held on April 16, 2026 (the “Annual Meeting”), for the purpose of voting on the five (5) proposals detailed in the Company’s Proxy Statement. There were present at the Annual Meeting by valid proxy the holders of 107,941,773 shares of the Company’s common stock, constituting a quorum.
Proxies for the meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934 and there was no solicitation in opposition to management’s nominees for directors. The voting results on each proposal submitted to the stockholders of the Company at the Annual Meeting are herein disclosed.
Proposal #1 : Each of the ten (10) nominees for director were elected to the Company’s Board of Directors. The term of office for each director will be until the next annual meeting or until their successors shall be elected and qualified. The voting results for each director were as follows:
Name For Against Abstained Broker Non-Votes
Raquel C. Bono, M.D. 101,247,023 852,333 103,372 5,739,045
Frank A. D’Amelio 97,025,521 5,065,710 111,497 5,739,045
David T. Feinberg, M.D. 100,915,674 1,169,313 117,741 5,739,045
Wayne A. I. Frederick, M.D. 85,170,452 16,912,783 119,493 5,739,045
Kurt J. Hilzinger 98,144,471 3,950,736 107,521 5,739,045
Karen W. Katz 99,324,708 2,762,723 115,297 5,739,045
Marcy S. Klevorn 101,233,979 854,134 114,615 5,739,045
Jorge S. Mesquita 101,329,642 742,426 130,660 5,739,045
James A. Rechtin 101,367,406 735,540 99,782 5,739,045
Gordon Smith 101,021,639 1,055,631 125,458 5,739,045
Proposal #2 : The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, was approved. The voting results were as follows:
For Against Abstained Broker Non-Votes
102,433,686 5,381,161 126,926 Not Applicable
Proposal #3 : The non-binding, advisory vote with respect to the Company’s executive compensation was approved. The voting results were as follows:
For Against Abstained Broker Non-Votes
97,237,851 4,669,732 295,145 5,739,045
Proposal #4 : The vote with respect to the Humana Inc. 2026 Stock Incentive Plan was approved. The voting results were as follows:
For Against Abstained Broker Non-Votes
97,655,200 4,295,549 251,979 5,739,045
Proposal #5 : The vote with respect to a stockholder proposal requesting shareholder approval requirement for excessive golden parachutes was not approved. The voting results were as follows:
For Against Abstained Broker Non-Votes
41,970,892 59,079,279 1,152,557 5,739,045
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
HUMANA INC.
BY: /s/ Valerie M. Talkers
Valerie M. Talkers
Vice President, Associate General Counsel & Corporate Secretary
Dated: April 20, 2026
Filing details
- Company
- HUMANA INC
- Ticker
- HUM
- CIK
- 49071
- Form type
- 8-K
- Filing date
- Apr 20, 2026
- Report date
- Apr 16, 2026
- Document
- hum-20260416.htm
- Size
- 160 KB